Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Timing and durability of response to erenumab in patients with chronic migraine

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Tepper, SJ, Lucas, S, Ashina, M, Schwedt, TJ, Ailani, J, Scanlon, J, Klatt, J, Chou, DE, Wang, A & Paiva da Silva Lima, G 2021, 'Timing and durability of response to erenumab in patients with chronic migraine', Headache, vol. 61, no. 8, 14193, pp. 1255-1263. https://doi.org/10.1111/head.14193

APA

Tepper, S. J., Lucas, S., Ashina, M., Schwedt, T. J., Ailani, J., Scanlon, J., Klatt, J., Chou, D. E., Wang, A., & Paiva da Silva Lima, G. (2021). Timing and durability of response to erenumab in patients with chronic migraine. Headache, 61(8), 1255-1263. [14193]. https://doi.org/10.1111/head.14193

CBE

Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G. 2021. Timing and durability of response to erenumab in patients with chronic migraine. Headache. 61(8):1255-1263. https://doi.org/10.1111/head.14193

MLA

Vancouver

Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J et al. Timing and durability of response to erenumab in patients with chronic migraine. Headache. 2021 Sep;61(8):1255-1263. 14193. https://doi.org/10.1111/head.14193

Author

Tepper, Stewart J ; Lucas, Sylvia ; Ashina, Messoud ; Schwedt, Todd J ; Ailani, Jessica ; Scanlon, James ; Klatt, Jan ; Chou, Denise E ; Wang, Andrea ; Paiva da Silva Lima, Gabriel. / Timing and durability of response to erenumab in patients with chronic migraine. In: Headache. 2021 ; Vol. 61, No. 8. pp. 1255-1263.

Bibtex

@article{638e0f99293044e9be4e395b1d52c48e,
title = "Timing and durability of response to erenumab in patients with chronic migraine",
abstract = "BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response.METHODS: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%).RESULTS: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188).CONCLUSION: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.",
keywords = "chronic migraine, erenumab, response patterns",
author = "Tepper, {Stewart J} and Sylvia Lucas and Messoud Ashina and Schwedt, {Todd J} and Jessica Ailani and James Scanlon and Jan Klatt and Chou, {Denise E} and Andrea Wang and {Paiva da Silva Lima}, Gabriel",
note = "{\textcopyright} 2021 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.",
year = "2021",
month = sep,
doi = "10.1111/head.14193",
language = "English",
volume = "61",
pages = "1255--1263",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell Publishing, Inc",
number = "8",

}

RIS

TY - JOUR

T1 - Timing and durability of response to erenumab in patients with chronic migraine

AU - Tepper, Stewart J

AU - Lucas, Sylvia

AU - Ashina, Messoud

AU - Schwedt, Todd J

AU - Ailani, Jessica

AU - Scanlon, James

AU - Klatt, Jan

AU - Chou, Denise E

AU - Wang, Andrea

AU - Paiva da Silva Lima, Gabriel

N1 - © 2021 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.

PY - 2021/9

Y1 - 2021/9

N2 - BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response.METHODS: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%).RESULTS: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188).CONCLUSION: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.

AB - BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response.METHODS: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%).RESULTS: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188).CONCLUSION: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.

KW - chronic migraine

KW - erenumab

KW - response patterns

UR - http://www.scopus.com/inward/record.url?scp=85112045384&partnerID=8YFLogxK

U2 - 10.1111/head.14193

DO - 10.1111/head.14193

M3 - Journal article

C2 - 34363708

VL - 61

SP - 1255

EP - 1263

JO - Headache

JF - Headache

SN - 0017-8748

IS - 8

M1 - 14193

ER -

ID: 67198634